CAR 疗法在肿瘤与自身免疫领域的演进:机制见解与治疗创新 The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations. PubMed 2026/05/16 发表Int ImmunopharmacolQ1 · IF 5.6(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T技术:基因编辑多发性骨髓瘤实体瘤淋巴瘤
靶向肿瘤坏死因子受体超家族成员 8 (CD30) 的 CAR-T 细胞治疗用于复发/难治性间变性大细胞淋巴瘤:原理、策略和新兴临床证据 Chimeric Antigen Receptor T‑Cell Therapy Targeting Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30) for Relapsed or Refractory Anaplastic La PubMed 2026/04/09 发表ACS Pharmacol Transl SciQ2 · IF 4(JCR 2025) 靶点:CD19靶点:CD30靶点:BCMA技术:CAR-T技术:基因编辑淋巴瘤
CRISPR/Cas9 TCR 编辑的 NKp30 CAR-T 细胞对表达 B7H6 的白血病与黑色素瘤表现出更强的抗肿瘤免疫 CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma. PubMed 2025/08/25 发表Int J Mol SciQ1 · IF 5.6(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T技术:造血干细胞技术:基因编辑急性髓系白血病多发性骨髓瘤淋巴瘤